康哲药业拟分拆德镁医药上市瞄准皮肤健康市场

证券日报2025-04-29

本报讯（记者李雯珊）近日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告，拟将旗下皮肤业务子公司德镁医药分拆并于中国香港联交所主板上市。分拆计划拟通过实物分派形式推进，康哲药业将其所持全部德镁医药股份按比例无偿分派给现有股东。德镁医药同日以介绍上市方式提交了上市申请，不涉及新股发行，股东权益不被稀释。　　公开资料显示，德镁医药业务围绕皮肤处方药及皮肤学级护肤品的研发产销，提供从预防、治疗到...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531126962?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-29 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531126962","market":"us","top_or_hot":-1,"title":"康哲药业拟分拆德镁医药上市 瞄准皮肤健康市场","media":"证券日报","content":"<div>\n<p>本报讯 （记者李雯珊）近日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告，拟将旗下皮肤业务子公司德镁医药分拆并于中国香港联交所主板上市。分拆计划拟通过实物分派形式推进，康哲药业将其所持全部德镁医药股份按比例无偿分派给现有股东。德镁医药同日以介绍上市方式提交了上市申请，不涉及新股发行，股东权益不被稀释。　　公开资料显示，德镁医药业务围绕皮肤处方药及皮肤学级护肤品的研发产销，提供从预防、治疗到...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202504293392497449.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业拟分拆德镁医药上市 瞄准皮肤健康市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业拟分拆德镁医药上市 瞄准皮肤健康市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-29 10:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202504293392497449.html><strong>证券日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>本报讯 （记者李雯珊）近日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告，拟将旗下皮肤业务子公司德镁医药分拆并于中国香港联交所主板上市。分拆计划拟通过实物分派形式推进，康哲药业将其所持全部德镁医药股份按比例无偿分派给现有股东。德镁医药同日以介绍上市方式提交了上市申请，不涉及新股发行，股东权益不被稀释。　　公开资料显示，德镁医药业务围绕皮肤处方药及皮肤学级护肤品的研发产销，提供从预防、治疗到...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202504293392497449.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"http://finance.eastmoney.com/a/202504293392497449.html","article_id":"2531126962","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531126962","pubTimestamp":1745892408,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"本报讯（记者李雯珊）近日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告，拟将旗下皮肤业务子公司德镁医药分拆并于中国香港联交所主板上市。分拆计划拟通过实物分派形式推进，康哲药业将其所持全部德镁医药股份按比例无偿分派给现有股东。德镁医药同日以介绍上市方式提交了上市申请，不涉及新股发行，股东权益不被稀释。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09939":"开拓药业-B","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1593":"医美概念股","BK1574":"生物医药B类股","SG9999015978.USD":"利安颠覆性创新基金A","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","BK1191":"制药","00867":"康哲药业","BK1515":"抗疫概念","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC"},"translate_title":"CMS plans to spin off Demagnesium Pharmaceuticals and go public to target the skin health market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1,"09939":1},"content_text":"本报讯 （记者李雯珊）近日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告，拟将旗下皮肤业务子公司德镁医药分拆并于中国香港联交所主板上市。分拆计划拟通过实物分派形式推进，康哲药业将其所持全部德镁医药股份按比例无偿分派给现有股东。德镁医药同日以介绍上市方式提交了上市申请，不涉及新股发行，股东权益不被稀释。　　公开资料显示，德镁医药业务围绕皮肤处方药及皮肤学级护肤品的研发产销，提供从预防、治疗到长期护理的皮肤健康综合解决方案。公司产品矩阵聚焦银屑病、白癜风、特应性皮炎、痤疮等高发皮肤病，瞄准临床未满足需求，具备差异化竞争力。　　近年来中国皮肤治疗和护理市场增长迅速，根据灼识咨询报告，中国的皮肤病治疗与护理市场于2023年的市场规模为764亿元，从2023年到2035年复合年增长率预计达到10.6%。德镁医药聚焦于皮肤健康领域，致力于实现皮肤领域主要疾病全覆盖，截至目前其在售、在研产品共十余款，不乏重磅品种，如JAK1/2芦可替尼乳膏、IL-23益路取（替瑞奇珠单抗注射液）、喜辽妥（多磺酸粘多糖乳膏）、抗IL-4Rα人源化单抗注射液MG-K10等，竞争力与市场潜力均十分突出。　　商业化能力方面，德镁医药拥有650多名专业人员组成的自建商业化团队，销售网络覆盖超1万家医院、超10万家线下零售药店，以及主流电商平台，占据有利竞争生态地位。据介绍，凭借卓越、行业领先的商业化能力，德镁医药2022年至2024年营业收入分别为3.84亿元、4.73亿元和6.18亿元，年均复合增长率达到26.8%。　　康哲药业相关人士表示，该分拆对余下集团和分拆集团均有裨益，体现在各自拥有独立的上市地位和融资平台、资源更聚焦、各自业务形象与市场地位提升、强化分拆集团员工股权激励等方面。（文章来源：证券日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531126962","isCrawlerRequest":true}

康哲药业拟分拆德镁医药上市 瞄准皮肤健康市场

精彩评论

康哲药业拟分拆德镁医药上市瞄准皮肤健康市场